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MicroRNAs (miRNAs) are evolutionarily conserved, naturally abundant, small, regulatory non-coding RNAs that
inhibit gene expression at the post-transcriptional level in a sequence-specific manner. Due to involvement in a
broad range of biological processes and diseases, miRNAs are now commanding considerable attention. Although
much of the focus has been on the role of miRNAs in different types of cancer, recent evidence also points to a
critical role of miRNAs in infectious disease, including those of bacterial origin. Now, miRNAs research is exploring
rapidly as a new thrust area of biomedical research with relevance to deadly bacterial diseases like Tuberculosis
(caused by Mycobacterium tuberculosis). The purpose of this review is to highlight the current developments in area
of miRNAs regulation in Mycobacterial diseases; and how this might influence the diagnosis, understanding of
disease biology, control and management in the future.
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Genomic studies revealed that numerous portions of the
human genome do not encode conventional protein-
coding genes but encode biologically active non-coding
RNA species. With the rapid expansion of small RNA
interference techniques over the past decade, it is now
clear that many small RNA molecules could regulate
gene and protein expression. One class of such small non-
coding RNAs is microRNAs (miRNAs), a group of regula-
tory RNAs of 19–22 nucleotides involved in control of
gene expression at the post-transcriptional level [1] thereby
acting as RNA interfering (RNAi) molecule. While a well-
known RNAi molecule, small interfering RNA (siRNA), is
a small RNA that is artificially synthesized, miRNA exists
endogenously in the cell. Therefore, miRNAs represents an
innate gene-silencing mechanism in our bodies.
miRNAs were first discovered in 1993 while studying
Caenorhabditis elegans [2]. The first miRNA discovered
was lin-4 that was found to play a role in the development
through a negative effect on lin-14 expression [2]. After
seven years (in 2000), let-7, the second miRNA was
discovered, again in the C. elegans [3]. In last decade,* Correspondence: devchauhan01@yahoo.co.in
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reproduction in any medium, provided the orsignificant advances have been made in miRNA research
leading to the discovery of more than 1,500 miRNAs that
have been fully characterized (as per miRBase database
viewed in Oct, 2012) and the number is expected to
grow in the coming years. Recent studies suggest that
miRNAs are involved in regulating cell fate (cell death
and proliferation), initiation and progression of human
cancer, developmental timing and orchestration of anti-
pathogenic responses [4-6].
In view of fact that the miRNAs regulates the expres-
sion of a number of genes, the dysregulation miRNAs
are being investigated extensively for a number of infec-
tious diseases. Although, early works were focused on
the role of miRNAs during viral and parasitic infections
[7-9], however in recent past, crucial relevance of
miRNAs in the interplay between host and bacteria has
been demonstrated [10]. This advancement has now
attracted the interest of researcher to dissect the role of
miRNAs in most deadly infectious human diseases like
Tuberculosis. The genus Mycobacterium includes highly
pathogenic species Mycobacterium tuberculosis (causing
tuberculosis) and Mycobacterium leprae (causing leprosy)
but also opportunists such as M. avium, which can also
cause disseminated infections in immuno-compromised
persons such as AIDS patients [11]. Despite advances intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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challenge to global public health in the 21st century.
Approximately one-third of humanity is infected, but
only 5-10% of this population develops active disease,
which in 2010 accounted for 8.8 million cases of 1.45
million deaths [12]. Unlike to tuberculosis control, last
three decades brought success in leprosy control world-
wide but recent emergence of 2,44,796 new cases of
leprosy in 2009 challenged both clinicians as well as
immunologists, especially in developing countries [13].
Though, interactions between Mycobacteria and its envir-
onment have been extensively studied, our knowledge at
the RNA level is still very limited. Study on deciphering
the role of miRNA in mycobacteial diseases, though
started very recently, provided some motivating and
interesting facts that need to be exploited in future
studies for better understanding of disease biology and
in designing the efficient control strategies. In this re-
view, we appraise the recent findings on regulation of
host miRNAs in response of Mycobacterial infection
and underpin the relevance of miRNAs in Tuberculosis.
Gene structure, biogenesis and basic function of miRNAs
The genesis of functional miRNAs involves a complex
multi-enzyme process leading from long precursor
molecules into ~22 nt long biologically active RNA
molecules. miRNAs are transcribed from their own
genes scattered in all chromosomes in humans, except
for Y chromosome [14]. Most miRNA genes are located
in intergenic regions (intergenic miRNAs) almost >1 kb
away from annotated/predicted genes, although some
miRNAs were found in intronic regions, within protein
coding-genes or in non-coding genes (intronic miRNAs)
[15]. Intergenic miRNAs are transcribed as autonomous
units with their own promoter/regulatory region, from
RNA Polymerase II or III; about a 50% of intergenic
miRNAs are found in close proximity to other miRNAs,
forming extended clusters which are transcribed as single
polycistronic unit [16]. Intronic miRNAs, residing within
protein coding genes or non-coding genes, seem to be
transcriptionally related to the expression of their host
gene and processed in consequence of the spliceosome
formation [17-19]. Transcription of intergenic miRNAs,
controlled by their own promoter, generates several
Kb- long pri-miRNAs with CAP structures and poly(A)
tails, which allow its subsequent processing reactions. On
the other hand, the transcription of intronic miRNAs
underlies the control of their host mRNAs using the same
promoter, and involves protein complexes of mRNAs spli-
cing machinery [20].
Genes encoding miRNA are generally transcribed in
the nucleus by RNA polymerase II (Pol II) into large pri-
mary miRNA transcripts (pri-miRNA) (sized >1 kb) that
undergo normal further processing i.e. 50-capping 30-polyadenylation or even splicing [21]. However, miRNAs
embedded in repetitive elements such as Alus can be
transcribed by RNA polymerase III [22]. These RNA
molecules form specific hairpin-shaped stem-loop second-
ary structures and enter a multi-enzyme complex known
as a microprocessor to be modified by the RNAse III en-
zyme Drosha and its co-factor, Pasha. This process leads
to the formation of a ~70 nt precursor miRNAs (pre-
miRNA) with a 50-phosphate and a 30- 2 nt long overhang
[23]. Thereafter, ras-related nuclear protein (RAN-GTP)
and exportin 5 mediate the export of pre-miRNAs from
nucleus to cytoplasm [24]. Cytoplasmic pre-miRNAs are
further processed by another RNAse III enzyme termed
Dicer to generate a transient ~22 nt long double stranded
miRNA [25]. This duplex is unwounded by helicases into
two single strands, one of which is then loaded into the
miRNA-associated multi-protein RNA-induced silencing
complex (RISC) which includes the Argonaute proteins
and induces gene silencing through mRNA cleavage,
translational repression or deadenylation. The other
strand, passenger strand, of duplex miRNA is degraded
[26,27] (Figure 1).
miRNAs are found in plants, animals, and other
diverse eukaryotes as well as a number of DNA viruses
where it negatively control the expression of target
genes. In plants and C. elegans, suppression of transcrip-
tion process was observed [28,29]. This suppression is
not a complete shut out, but rather miRNAs are now
revealed to fine tune / modulate the rate of mRNA.
Though, a few different hypothesis have been given on
the action of miRNAs, in general, miRISC with miRNA
moves toward the target mRNA, and binds miRNA in
the complementary region in the 30 untranslated region
(30 UTR) to either terminate the translation or to lead to
degradation of the mRNA to interfere with the gene
expression [30,31]. Once the miRNA is bound to a com-
pletely complementary region of mRNA, like siRNA,
mRNA gets degraded. However, miRNA mediated regu-
lation does not require to have a perfect match with its
target-binding region. Only, 7-base sequence between
2nd and 8th nucleotide from the 50 end is called “seed
region,” and a complete match of the sequence is
required. It is believed that the strength of the inhibition
varies depending on the sequence but, how it is done at
good balance yet to be revealed. A single miRNA may
directly affect the expression of hundreds of proteins at
once and several miRNAs can also target the same
mRNA and result in enhanced translational inhibition
[32]. The exact mechanisms of gene repression are still
being elucidated, but there is evidence for translational
initiation inhibition, translational elongation inhibition,
premature translational termination, and co-translational
protein degradation [33]. Moreover, these recent studies
have introduced a paradigm shift in our understanding
Figure 1 The linear synthetic pathway of micro-RNA biogenesis.
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believed to be universal to all miRNAs.
miRNAs and its relation with bacterial infection
Considering that more than 1,000 miRNAs have been so
far annotated in the human genome and that individual
miRNAs can have hundreds of targets, it has been
predicted that roughly 60% of the human transcriptome
may be regulated by miRNAs, although it remains un-
clear that how many of these are physiologically relevant
targets [34]. The complex regulatory role of miRNA
adds another layer to an already complex gene regula-
tory network involved in various biological processes as
well as pathogenesis of diseases. There is increasing
evidence suggesting that miRNAs play critical roles in
many key biological processes, such as cell growth, tissue
differentiation, cell proliferation, embryonic develop-
ment, and apoptosis [35]. The most widely expanding,
however, is the disease-related miRNA research based
on miRNA expression analysis, probably due to the fact
that generalized functional mechanisms were discovered
for all miRNA. As per a manually curated, publicly avail-
able database (miR2disease.org), more than 150 humandiseases (as viewed on Jan, 2013) have been documented
to have relationship with miRNAs dysregulation [36].
Although, most of the evidences on involvement of
microRNAs in diseases come from cancer research, the
dysregulation of microRNAs has been associated with
several other diseases viz., neurodegenerative, cardiovas-
cular, pulmonary diseases, liver, kidney, brain and auto-
immune diseases. In addition to well established function
in physiological and pathological process, miRNAs are in-
creasingly implicated in eukaryotic response to infectious
pathogens. This area of research is now gaining the mo-
mentum to increase our understanding on complex biol-
ogy of several infectious diseases.
With respect to infectious diseases, noticeable works
was presented on miRNAs regulation in response to
viruses and parasites. However, the role of miRNAs in
bacterial infection is comparatively less explored area,
but recent quantum jump discovered numerous miRNA
regulation/ mis-regulation in response to a range of bacter-
ial infections. The first report on role of miRNAs in bacter-
ial infections was documented in plants where Arabidopsis
miR-393 contributed to resistance against the extracellular
bacteria Pseudomonas syringae, presumably by repressing
Singh et al. Journal of Biomedical Science 2013, 20:14 Page 4 of 9
http://www.jbiomedsci.com/content/20/1/14auxin signalling [37]. After this first evidence,
the regulations of mammalian miRNAs in response
to bacterial infection are increasingly investigated.
Helocobacter pylori is the main cause of peptic ulcer-
ation in human and gastric adenocarcinoma in human
[38,39]. Currently, a study showed that H. pylori
infections alter the expression of oncogenes, tumor
suppressor genes and miRNAs [39]. Salmonella has
been also found to significantly induce several miRNAs
(like miR-155, miR-146a andmiR-21) [40]. Treatment of
immune cells with bacterial lipopolysaccharide (LPS)
from Salmonella and Escherichia coli led to the induc-
tion of miR-155, miR-132 and miR-146 expression [41].
The diverse miR-155 response to two subspecies
of Francisella tularensis, a highly infectious Gram-
negative bacterium that causes tularaemia has been
reported [42]. Similarly to Gram-negative bacteria, Listeria
monocytogenes (Gram-positive bacteria), also induce sig-
nificant changes in the miRNA profile of bone marrow-
derived macrophages. Particularly, miR-155, miR-146a,
miR-125a-3p/5p, and miR-149 all of which are implicated
in regulation of immune related genes, were significantly
induced [43]. The rapid progress in miRNA research has
provided some concrete evidences on pivotal role of
miRNAs in Mycobacterial diseases that are discussed
below in detail.
miRNAs regulation in response to Mycobacterial infection
The exact molecular pathogenesis of tuberculosis and
other Mycobacterial diseases is not yet completely
understood and this is one of the major hurdle inTable 1 Regulation of host micor-RNAs in response to Mycob
Mycobacterium species Cells/samples and their source
Mycobacterium tuberculosis
(M.tb)
Human monocyte derived macrophages
PBMCs from TB patients
Serum from TB patients
Sputum from TB patients
M.tb infected bone marrow derived murine
macrophages
Mycobacterium leprae Skin biopsy from Leprosy patients
PBMCs from Leprosy patients
Mycobacterium bovis Murine T cells
Mycobacterium avium Human monocyte derived macrophages
Mycobacterium smegmatis Human monocyte derived macrophagescontrol of Mycobacterial disease especially Tuberculosis.
The slow growth of Mycobacterium tuberculosis, coupled
with many other quirks, make it a frustrating organism
to deal with, while laboratory culture of the other major
pathogen, Mycobacterium leprae (M. leprae), remains an
elusive dream. Moreover, the tubercle bacillus has learnt
how to defend itself against the existing drug regimens
and the emergence of multi and extensive drug-resistant
strains of M. tuberculosis is now a very real threat to
world health. In general, intricate regulation of various
eukaryotic/ host genes is crucial in the development of
disease, and current understanding of miRNAs has
unveiled a new layer of eukaryotic gene expression regula-
tion unravelling several unsolved biological mechanisms
in development or disease. This is why, now researchers
are giving considerable attention to elucidate the relation-
ship between miRNAs and Mycobacterial infection.
Tables 1 and 2 summarize the available reports on the
modulation of host miRNAs by some of studied Mycobac-
terium species.
miRNAs have been found in tissues and also in serum
and plasma, and other body fluids, in a stable form that
is protected from endogenous RNase activity (in associ-
ation with RISC, either free in blood or in exosomes
(endosome-derived organelles)). The potential for the
use of these circulating miRNAs as biomarkers of dis-
ease and as targets of therapeutics is promising for vari-
ous diseases especially cancer [44]. In view of potential
significance of circulating miRNAs, the first success in
clarification that miRNAs takes role in pulmonary tuber-
culosis pathogenesis was published in 2011 [45] in whichacterial pathogens
Regulated miRNAs Reference
Up: miR-125b
Rajaram et al. [49]
Down: miR-155
Up: miR-144*, miR-155, miR-155* Liu et al. [53]
Wu et al. [50]
Up: miR-29a Fu et al. [45]
Up: miR-3179, miR-147, miR-29a Yi et al. [46]
Down: miR-19b-2* Fu et al. [45]
Up: miR-155 Kumar et al. [51]
Up: miR-21 Liu et al. [54]
Down: mir-181a Kumar et al. [56]
Down: miR29 Ma et al. [48]
Up: miR-155, miR-146a/b, miR-886-5p, let-7e,
let-7i, miR-29a
Sharbati et al. [47]
Down: miR-20a, miR-191, miR-378, miR30c, miR-
423-5p,
miR-374a, miR-185, miR-768-5p
Up: miR-155 Rajaram et al. [49]
Table 2 Identified micro-RNAs mediated modulation of host response during Mycobacterial infection/ stimulation
Micro-RNAs Identified regulation mechanism Reference
miR-29 Suppress the IFN-γ production by targeting IFN-γ mRNA Ma et al. [48]
miR-29 and Let-7e Inhibit the apoptosis by caspases 3 and 7 (major effector caspases) Sharbati et al.[47]
miR 125b Block the TNF-α biosynthesis Rajaram et al. [49]
miR-155 Enhance the TNF-α biosynthesis Rajaram et al. [49]
miR-155 Repress Bach1 and SHIP1 to support the dormancy and survival of M. tuberculosis in host Kumar et al. [51]
miR-99b Negatively regulate the production of proinflammatory cytokine that leads to reduced growth of M.
tuberculosis
Singh et al, [50]
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and active pulmonary tuberculosis was investigated by
micro-array based expression profiling method. Among
92 miRNAs detected significantly, 59 miRNAs were
downregulated and 33 miRNAs were upregulated in the
TB serum compared to their levels in the control serum.
Interestingly, on validating the micro-array results with
real time PCR, differentially increased expression of miR-
29a and miR-93* was found not only in the serum but also
in the sputum of patients with active pulmonary tubercu-
losis as compared to healthy controls [45]. After this first
description, subsequently, genome wide miRNA expres-
sion in sputum supernatant of patients with active pul-
monary tuberculosis was also delineated in recent past
[46]. In this study, a total of 95 miRNAs were found to be
expressed differentially by microarray and miR-3179, miR-
147 overexpressed and miR-19b-2* suppressed in TB
patient group compared with controls as observed in the
validation cohort by real time PCR.
In 2011, Sharbati and co-workers [47] demonstrated
how distinct mycobacteria could manipulate host cell re-
sponse by studying the regulatory network of potential
interactions between miRNAs and mRNAs. The human
macrophages infected with M. avium revealed that many
of the differentially regulated miRNAs showed decreased
expression (e.g., miR-20a, miR-191, miR-378, miR-185),
whereas miR-155, miR-146a/b, miR-886-5p, miR-29a
and let-7e were induced upon mycobacteria infection.
The integrated analysis of miRNA and mRNA expres-
sion as well as target prediction and reporter assays
identified caspases 3 and 7, major effector caspases
essential in the triggering of apoptosis, as targets of let-7e
and miR-29a, respectively, thus showing that inhibition of
apoptosis after mycobacterial infection is controlled
by miRNAs. The pivotal role of miR-29 was also
demonstrated in T cells of mice infected with Listeria
monocytogenes or Mycobacterium bovis bacillus Calmette-
Guerin (BCG) [48]. However, in contrary to above
observed induction of miR-29a, down-regulated expression
of miR-29 in IFN-γ-producing natural killer cells, CD4+ T
cells, and CD8+ T cells was observed. Interestingly, it was
demonstrated that miR-29 directly target IFN- γ mRNA
and suppress the production of IFN-γ [48].Additionally, differential miRNA regulation was also
reported recently in response to high virulent Myco-
bacteria (M. tuberculosis) as compared to low virulent
(M. smegmatis) in infected human macrophages [49].
Macrophages incubated with surface molecule (lipomannan)
of M.tuberculosis and live induce high miR-125b ex-
pression and low miR-155 expression with correspond-
ingly low TNF production. Whereas, lipomannan of M.
smegmatis and live induce high miR-155 expression and
low miR-125b expression with high TNF production. The
differential induction of TNF-α biosynthesis by the two
mycobacteria species may be understood as; miR-125b
directly targets the TNF-α mRNA, while miR-155 probably
indirectly enhances TNF-α production by increasing
TNF-αmRNA half-life and translation [41]. Therefore, high
levels of miR-125b induced by M. tuberculosis, leads to the
blocking of TNF biosynthesis, thereby allowing M. tubercu-
losis to subvert host immunity and potentially increase its
virulence. In a very latest study, miR-99b mediated
TNF-α modulation was also demonstrated that affects
the bacterial growth in M. tuberculosis-infected dendritic
cells [50]. Since, knockdown of miR-99b in dendritic cells
associated with enhanced production of proinflammatory
cytokines and significantly reduced bacterial growth, it will
be interesting to explore further the potential of miR-99b
to be used as therapeutics/ biomarker for tuberculosis. In
a different study, higher expression of miR-155 and miR-
155* was observed in stimulated PBMCs (with tuberculin;
antigen mixture of standard H37Rv strain of M.tubercu-
losis) of active tuberculosis patients as compared to un-
stimulated [51]. Therefore, tuberculin-induced increased
expression of miR-155 and miR-155* explored its future
exploitation as a diagnostic biomarker. However PPD is
not considered a reliable stimulator, and it may trigger
false-positive results in BCG-vaccinated or tuberculin-
positive individuals. Very recently, specific secretory M.
tuberculosis antigen, ESAT-6 was also found to play a key
role in miR-155 induction and its subsequent effects on
Bach1 and SHIP1 repression [52]. It is known that Bach1
is a transcriptional repressor of heme oxygenase-1 (HO-1;
a documented activator of the M.tuberculosis dormancy),
whereas SHIP1 inhibits the activation of the serine/threo-
nine kinase AKT (required for M.tuberculosis survival).
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modulation of host innate immunity and for protection
against M. tuberculosis infection. M. bovis BCG was also
found to trigger Toll-like receptor 2 (TLR2)-dependent
miR-155 expression that takes part in mediating the apop-
tosis of macrophages through complex signaling pathways
[53]. Thus it again suggested the importance of miR-155
and its role in orchestrating cellular reprogramming in
response to Mycobacterial infection.
In addition to miR-155, the role of miR-144* precursor
in modulation of anti-TB immunity through modifica-
tion of cytokine production and cell proliferation of T
cells was also demonstrated [54]. Besides, overexpression
of miR-144* precursor in PBMCs of pulmonary tubercu-
losis cases, transfection of T cells with miR-144* precursor
demonstrated that miR-144* might inhibit TNF-α and
IFN-γ production and T cell proliferation.
Recently, miRNA expression in leprosy skin lesions
was also investigated in which 13 miRNAs were found
to be expressed differentially in the lesions of human
subjects with progressive lepromatous (L-lep) versus the
self-limited tuberculoid (T-lep) disease [55]. mir-21,
most differentially expressed miRNA in L-lep lesions
was also overexpressed in M.leprae infected monocytes.
Notably, it was also experimentally demonstrated that
mir-21 inhibits the expression of the genes encoding two
vitamin D–dependent antimicrobial peptides, CAMP
and DEFB4A probably by direct downregualation of
Toll-like receptor 2/1 heterodimer (TLR2/1)-induced
CYP27B1 and IL1B expression as well as indirectly
upregulating interleukin-10 (IL-10). It is again note-
worthy that knockdown of mir-21 in M. leprae-infected
monocytes enhances the expression of CAMP and
DEFB4A and restore TLR2/1-mediated antimicrobial
activity against M. leprae. Therefore, study strongly
suggests that mir-21 can potentially downregulate host
defense genes (to escape from vitamin D–dependent
antimicrobial pathway) in leprosy. NF-kB activation
mediated upregulation of miR-21 in response to Bacillus
Calmette-Guerin (BCG) vaccination was also delineated
in recent past [56]. Additionally, the role of miR-21 in
suppression of IL-12 production (by targeting IL-12p35)
and inducted dendritic cell apoptosis (by targeting Bcl-2)
was mark out in BCG-vaccinated bone marrow derived
macrophages. Therefore, this study again streng-
thened the role of miR-21 in fine-tuning of the anti-
mycobacterial response in general and regulating the
efficacy of BCG vaccination in particular. Besides the
critical role of miR-21 in leprosy, miR-181a is another
important RNA molecule which down-regulated expres-
sion may be associated with leprosy progression [57].
Furthermore, it was suggested that miR181a may con-
tribute to overexpression of SHP2 that lead to T cell
hyporesponsiveness during leprosy progression. Keepingall the above recent finding in notion, it is now clear that
Mycobacteria can induce miRNA expression in immune
cells and also miRNA plays important role both in pro-
gression as well as protection of Mycobacterial diseases.
Role of miRNAs as biomarker and therapeutics in
Mycobacterial diseases
miRNA expression profiling is of increasing importance as
it’s exploitation in development of reliable diagnostic and
prognostic biomarkers. In last few years, studies especially
on role of miRNAs in different types of cancer have shown
that miRNA expression profiles may classify the tumors
and also it may potentially be used as biomarker for diag-
nosis and disease progression [58,59]. Encouraged with
cancer studies, the role of miRNAs in infectious diseases
including bacterial diseases was investigated. Although,
some tantalizing evidences has been put forward on the
possible role of miRNAs as biomarker for bacterial
diseases including Mycobacterial infection, continued and
extensive works however warranted in light of the marked
global health impact of tuberculosis and problems
associated with its diagnosis. As discussed in previous sec-
tion, differential miRNA levels have been found in PBMCs
[51,54], serum [45] and sputum [46] of TB patients as
compared with healthy control. Of the various miRNAs,
miR-29a, miR-155, miR-155*, miR-125b, miR-3179a
and miR-147 may be of potential biomarker for diagnosis
of tuberculosis (Table 1). Although, these miRNAs
biomarkers have been identified by some independent
groups but still it could not be validated adequately.
Moreover, if we consider that these have potential to dis-
criminate active and / or latent tuberculosis from healthy
individuals, the question remains whether these gene ex-
pression signatures are specific for TB or shared, at least
in part, with diseases of similar pathology but distinct eti-
ology. This important issue was investigated in a recent
study, in which whole blood miRNAs signatures of tuber-
culosis was compared with sarcoidosis that is known to
have similar pathology [60]. This study showed significant
differences in expression between healthy and diseased
individuals, however, both TB and sarcoidosis revealed
highly similar miRNAs profiles. The similarity of miRNAs
profile may be due to the fact that miRNAs are primarily
responsible for fine tuning of responses rather than on/off
switch signals [61]. Therefore, on the basis of current
understanding on this aspect, future works need on identi-
fying the biomarkers by not only focusing on differential
expression but also expression in diseases with similar
pathology or diseases caused by closely related pathogens
(like Mycobacterium species).
Besides use as a biomarker, another translational applica-
tion of miRNAs has been explored as therapeutics. There
are two main strategies for developing drugs targeting
miRNA: (1) by suppressing the disease-specific miRNAs
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supplementing miRNA whose expression decreased.
Tremendous efforts and progress are being made for
the development of miRNAs based drugs especially for
cancer [62] and Hepatitis C virus infection [63]. The
differentially expressed miRNAs found in response to
Mycobacterial infection (Table 1) may have potential as
future therapeutics however, no clinical trials and pro-
gress in this line have been made so far.
Future direction: Expectation and limitation
Despite of several advancement and rigorous research of
last several decades, tuberculosis remains most deadly,
major threat to mankind and an enigmatic infectious
disease. Of the various research efforts in diverse
directions for the control of tuberculosis, recently identi-
fied involvement of miRNA in mycobacterial infection
has also nourished the hopes for better understanding of
pathogenesis, developing new class of sensitive and
accurate diagnostic and prognostic biomarkers and
possible new therapeutics for tuberculosis. But currently
this area is in its infancy and demanding more attention
and continued works towards understanding the com-
plex regulation of miRNA regulation in tuberculosis and
further its exploitation to add the rational design for the
effective control and management of tuberculosis. The
accurate and rapid diagnosis as well as ability to monitor
the treatment response is very crucial for effective con-
trol and management of tuberculosis. Although few
miRNAs has been identified having ability to differen-
tially diagnose the active TB and latent TB from healthy
individuals [45,64] but whether such biomarkers are of
TB or shared by other diseases is yet not clear. Therefore,
along with developing reliable miRNAs based biomarkers,
future works are needed to discover biomarkers for the
prediction of relapse, sterilizing activity and treatment re-
sponse on account to provide batter treatment as well as
to facilitate the testing of new drugs.
Recent landmark in- vitro and in-vivo studies in Myco-
bacterial diseases showed that miRNA species, regulating
immune modulatory genes directly or indirectly, can affect
the downstream effectors of an innate immune-triggered
antimicrobial pathway [48,54] and thereby contributing in
development of disease. This knowledge may have
implications for the development and improvement of
future approaches for the prevention and therapy of
tuberculosis. Since the identification of disease-specific
miRNAs that cause the onset or exacerbation will lead
to intellectual property as well as drug development,
great efforts are made to research and develop them
worldwide especially in cancer and a few other diseases.
Although there are some successes and few miRNAs
targeting drugs are currently under different phase of
clinical trials, still suitable delivery system for miRNAdrug and it’s sustaining potency inside the body still
need considerable attentions in future research. Re-
cently, potential target sites of known human miRNAs
were identified in M. tuberculosis genome by in-silico
prediction method [65]. However, due to limitations of
current miRNA target prediction programs, experimen-
tal validation of predicted miRNA targets is necessary
to confirm. If host cell miRNAs are proven to play a
role in regulating the intricate networks involved in
human-M.tuberculosis interaction, it will open up a
new area in both miRNA and M. tuberculosis research.
The limitation to applicability of miRNAs as bio-
marker and therapeutics reflected by the very basic and
still unresolved question as to whether the increase or
decrease of miRNA expressions actually cause the dis-
ease or if they are a consequence of the disease. Add-
itionally, it is known that miRNAs contribute in various
biological processes and single miRNA may modulate
the expression of hundreds of genes therefore adminis-
tration of miRNA as drug to cure any targeted disease,
may lead to unwanted gene silence. Therefore, the above
challenges should be kept in notion while taking the ini-
tiative for the development of miRNAs targeted/ based
biomarkers or therapeutics for tuberculosis or other
diseases. Overall, in future greater emphasize on basic re-
search is needed simultaneous with research for transla-
tional application of miRNAs in mycobacterial diseases,
especially in tuberculosis.
Conclusions
miRNAs represent a relatively young field of basic bio-
logical and translational research into new and innovative
therapeutic applications. Tantalizing preliminary evidence,
miRNAs have altered expression and are able to modulate
the host antibacterial pathways in response to Mycobacter-
ial infection, have created new opportunities in tubercu-
losis research. Since research on similar line begun only
recently, the future research on identification and detail
understanding of how host cell miRNAs regulate Mycobac-
terial infection will be of exquisite importance in view of de-
velopment of novel biomarkers and therapeutics. The rapid
advancement and explosion in miRNA research nourishes
our hope for a giant leap in better diagnosis and treatment
of infectious diseases including tuberculosis in future.
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